sglt2 glp-1 news GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog SGLT2 inhibitors and GLP-1 receptor

Tissue perfusion and sexual function pathways A case report of female anorgasmia and hypoarousal temporally related to GLP-1 agonist use (including semaglutide after a switch from liraglutide) proposed mechanisms including smooth-muscle vasoconstriction with reduced genital blood flow and central neurotransmitter pathway effects (hypothalamic signalling)

Its documented effect is on visceral adipose tissue, the deep abdominal fat wrapped around organs, which is the same fat that increases cardiovascular and metabolic risk

Among the diseases it can potentially treat are Parkinson's disease, Alzheimer's disease, and Huntington's disease

Visual inspection alone isn't enough if you're serious about efficacy

A doctor can also guide you on the type of treatment that would be most effective for you

10.1016/j.soc.2016.05.009 39